The Discounted Cash Flow (DCF) valuation of Sinphar Pharmaceutical Co Ltd (1734.TW) is 39.13 TWD. With the latest stock price at 31.70 TWD, the upside of Sinphar Pharmaceutical Co Ltd based on DCF is 23.4%.
Based on the latest price of 31.70 TWD and our DCF valuation, Sinphar Pharmaceutical Co Ltd (1734.TW) is a buy. buying 1734.TW stocks now will result in a potential gain of 23.4%.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 6.9% | 5.9% |
| Long-term Growth Rate | 2.0% - 4.0% | 3.0% |
| Fair Price | 22.15 - 130.53 | 39.13 |
| Upside | -30.1% - 311.8% | 23.4% |